NCT01855854 2019-07-05Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISHBetta Pharmaceuticals Co., Ltd.Phase 2 Completed54 enrolled